



Image

PATENT APPLICATION

6P/1647

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boyle

Serial No.: 09/211,315

Group Art Unit No.: 1647

Filed: December 14, 1998

Examiner: Nichols, Christopher J.

For: Osteoprotegerin Binding Proteins

Docket No.: A-451J

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicant submits a copy of each of the references listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner.

Applicant, by the undersigned attorney/agent, certifies that no information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than [30 days pursuant to 37 C.F.R. 1.704(d) or] three months pursuant to 37 C.F.R. 1.97(e)(1) prior to the filing of this statement.

Applicant(s) request(s) consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Please send all future correspondence to:
U.S. Patent Operations/RBW
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date: March 2, 2004

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

3/2/04
Date

Robert B. Winter
Signature



Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.	Serial No.
	A-451J	09/211,315
	Applicant	
	Boyle	
	Filing Date	Group
	December 14, 1998	1647

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	5,763,223	09/06/98	Wiley et al.			
	A2	5,961,974	05/10/99	Armitage et al.			
	A3	6,017,729	25/01/00	Anderson et al.			
	A4	6,150,090	21/11/00	Baltimore et al.			
	A5	6,242,213	05/06/01	Anderson			
	A6	6,410,516	25/06/02	Baltimore et al.			
	A7	6,419,929	16/07/02	Anderson			
	A8	6,525,180	25/02/03	Gorman et al.			
/	A9	09/957,944	Filed: 20/09/01	Dougall			
	A10	10/151,071	Filed: 17/05/02	Dougall et al.			
	A11	10/166,232	Filed: 05/06/02	Dougall			
	A12	10/405,878	Filed: 01/04/03	Anderson			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
/	B1	EP 0816380	07/01/98	Europe				
/	B2	EP 0873998	28/10/98	Europe				
/	B3	WO 96/34095	31/10/96	PCT				
/	B4	WO 98/28423	02/07/98	PCT				
/	B5	WO 98/54201	03/12/98	PCT				
/	B6	WO 99/65449	23/12/99	PCT				
/	B7	WO 99/65495	23/12/99	PCT				
/	B8	WO 01/23549	05/04/01	PCT				
/	B9	WO 02/15846	28/02/02	PCT				

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.	Serial No.
	A-451.I	09/211.315
	Applicant	
	Boyle	
	Filing Date	Group
	December 14, 1998	1647

EXAMINER'S
INITIALS

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

✓	C1	Boyle v. Gorman and Mattson, Board of Patent Appeals and Interferences, Interference No. 104,336, Paper No. 39
✓	C2	Camerini et al., <i>J. Immunol.</i> , "The T Cell Activation Antigen CD27 is a Member of the Nerve Growth Factor/Tumor Necrosis Factor Receptor Gene Family", 147:3165-3169 (1991).
✓	C3	Caux et al., <i>J. Exp. Med.</i> , "Activation of Human Dendritic Cells through CD40 Cross-linking", 180:1263-1272 (1994).
✓	C4	Dürkop et al., <i>Cell</i> , "Molecular Cloning and Expression of a New Member of the Nerve Growth Factor Receptor Family That Is Characteristic for Hodgkin's Disease", 68:421-427 (1992).
✓	C5	EMBL-EBI Database Entry HS421358, Accession No. W74421, Homo Sapiens cDNA Clone IMAGE:346544 3' Similar to Contains Alu Repetitive Element, Hillier et al., (June 1996).
✓	C6	Galibert et al., <i>J. Biol. Chem.</i> , "The Involvement of Multiple Tumor Necrosis Factor Receptor (TNFR)-Associated Factors in the Signaling Mechanisms of Receptor Activator of NF- κ B, a Member of the TNFR Superfamily", 273(51):34120-34127 (1998).
✓	C7	Gray et al., <i>Genetics</i> , "P-Element-Induced Recombination in <i>Drosophila melanogaster</i> : Hybrid Element Insertion", 144(4):1601-1610 (1996).
✓	C8	Itoh et al., <i>Cell</i> , "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis", 66:233-243 (1991).
✓	C9	Johnson et al., <i>Cell</i> , "Expression and Structure of the Human NGF Receptor", 47:545-554 (1986).
✓	C10	Kodaira et al., <i>Gene</i> , "Cloning and characterization of the gene encoding mouse osteoclast differentiation factor", 230:121-127 (1999).
✓	C11	Kwon et al., <i>Proc. Natl. Acad. Sci. USA</i> , "cDNA sequences of two inducible T-cell genes", 86:1963-1967 (1989).
✓	C12	Mallett et al., <i>EMBO J.</i> , "Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes—a molecule related to nerve growth factor receptor", 9:1063-1068 (1990)
✓	C13	NCBI, Marra et al., The WashU-HHMI Mouse EST Project, GenBank Accession No. AA170348, (16 Feb. 1997).
✓	C14	Nakagawa et al., <i>Biochem. Biophys. Res. Commun.</i> , "RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis", 253:395-400 (1998).
✓	C15	Romani et al., <i>J. Exp. Med.</i> , "Proliferating Dendritic Cell Progenitors in Human Blood", 180:83-93 (1994).
✓	C16	Rothe, M. et al., <i>Cell</i> , "The TNFR2-TRAF Signaling Complex Contains Two Novel Proteins Related to Baculoviral Inhibitor of Apoptosis Proteins", 83:1243-1252 (1995).
✓	C17	Schall, et al., <i>Cell</i> , "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor", 61:361-370 (1990).
✓	C18	Simonet et al., <i>Cell</i> , "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density", 89:309-319 (1997).
✓	C19	Stamenkovic et al., <i>EMBO J.</i> , "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas", 8:1403-1410 (1989).
✓	C20	Suda et al., <i>Endocr. Rev.</i> , "Modulation of Osteoclast Differentiation", 13:66-80 (1992).
✓	C21	Suda et al., <i>Bone</i> , "Modulation of Osteoclast Differentiation by Local Factors", 17(2):87S-91S (1995).

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Modified Form PTO-1449

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.

A-451.J

Serial No.

09/211.315

Applicant

Boyle

Filing Date

December 14, 1998

Group

1647

EXAMINER'S
INITIALS**OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)**

✓	C22	Suda et al., <i>Endocr. Rev.</i> , <i>Monograph</i> , "Modulation of Osteoclast Differentiation: Update 1995", 4(1):266-270 (1995).
✓	C23	Viney et al., <i>J. Immunol.</i> , "Expanding Dendritic Cells In Vivo Enhances the Induction of Oral Tolerance", 160:5815-5825 (1998).
✓	C24	Wong et al., <i>J. Biol. Chem.</i> , "The TRAF Family of Signal Transducers Mediates NF- κ B Activation by the TRANCE Receptor", 273(43):28355-28359 (1998).
✓	C25	Wong et al., <i>J. Exp. Med.</i> , "TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell-specific Survival Factor", 186:2075-2080 (1997).
✓	C26	Xu et al., <i>Immunity</i> , "Targeted Disruption of TRAF3 Leads to Postnatal Lethality and Defective T-Dependent Immune Responses", 5:407-415 (1996).
✓	C27	Yun et al., <i>Immunol.</i> , "OPG/FDCR-1, a TNF Receptor Family Member, Is Expressed in Lymphoid Cells and Is Up-Regulated by Ligating CD40", 161:6113-6121 (1998).
	C28	
	C29	
	C30	
	C31	
	C32	
	C33	
	C34	
	C35	
	C36	
	C37	
	C38	
	C39	
	C40	
	C41	
	C42	
	C43	
	C44	

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.